首页> 外文OA文献 >Anti-RNA polymerase antibodies in systemic sclerosis (SSc): association with anti-topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II
【2h】

Anti-RNA polymerase antibodies in systemic sclerosis (SSc): association with anti-topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II

机译:系统性硬化症(SSc)中的抗RNA聚合酶抗体:与抗拓扑异构酶I抗体的关联以及RNA聚合酶II的自身反应性亚基的鉴定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The prevalence of autoantibodies to the three RNA polymerase (RNAP) enzymes in the sera of 249 SSc patients was measured using the technique of immunoprecipitation of 35S-methionine-labelled K562 cell extracts. Forty-six anti-RNAP sera were detected (18.5%) and three main groups were identified: anti-RNAP I/III sera (10; 4.0%), anti-RNAP I/II/III sera (15; 6.0%), and sera precipitating the phosphorylated (IIO) form of RNAP II (18; 7.2%). All sera in the third group also precipitated topoisomerase I (topo I), and six of them also precipitated the unphosphorylated (IIA) form of RNAP II. Although RNAP II/topo I multienzyme complexes may occur in cell extracts, autoreactive epitopes were shown to be located on both enzymes by a combination of antigen depletion studies, and in vitro assays which demonstrated functional inhibition of topo I activity. Furthermore, immunoblotting experiments using affinity-purified extracts demonstrated that all sera with anti-RNAP II antibodies recognized the largest RNAP II subunit in its phosphorylated form (IIo; 240 kD), whereas the unphosphorylated subunit (IIa; 220 kD) was only recognized by sera which also precipitated RNAP IIA. Therefore at least two different sites on the largest subunit of RNAP II are recognized by SSc sera, and one of these sites is unique to the phosphorylated (IIO) form.
机译:使用35S-甲硫氨酸标记的K562细胞提取物的免疫沉淀技术测量了249名SSc患者血清中三种抗体的自身抗体的流行率。检测到46种抗RNAP血清(18.5%),并确定了三个主要类别:抗RNAP I / III血清(10; 4.0%),抗RNAP I / II / III血清(15; 6.0%),并沉淀出磷酸化(IIO)形式的RNAP II(18; 7.2%)。第三组中的所有血清也沉淀了拓扑异构酶I(拓扑I),其中六个也沉淀了RNAP II的未磷酸化(IIA)形式。尽管RNAP II /拓扑I多酶复合物可能会出现在细胞提取物中,但结合抗原耗竭研究和体外试验表明,功能上抑制了拓扑I活性,自反应性表位位于两种酶上。此外,使用亲和纯化的提取物进行的免疫印迹实验表明,所有具有抗RNAP II抗体的血清均以其磷酸化形式(IIo; 240 kD)识别最大的RNAP II亚基,而未磷酸化的亚基(IIa; 220 kD)仅被也沉淀RNAP IIA的血清。因此,SSc血清可识别RNAP II最大亚基上的至少两个不同位点,而这些位点之一是磷酸化(IIO)形式所独有的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号